Chaplin’s World Misses Record Attempt.

Chaplin’s World in Switzerland celebrated its tenth anniversary with a unique tribute to legendary filmmaker Charlie Chaplin. Hundreds of fans dressed as the iconic actor gathered at the museum in Corsier-sur-Vevey on Sunday, hoping to break the world record for the largest gathering of Charlie Chaplin look-alikes.

A total of 429 participants arrived wearing Chaplin’s signature outfit, including the famous black bowler hat, moustache, suit, and walking stick. Together, the participants formed a giant number “10” in the gardens of the historic Ban mansion, marking a decade since the museum first opened its doors.

Despite the enthusiastic turnout, the event fell short of its ambitious goal. Organisers had hoped to attract 1,000 participants and surpass the existing record. However, the final count remained well below the 662 look-alikes who gathered at the same location in 2017, meaning the record remains unbeaten.

The anniversary event was part of a broader programme of celebrations planned throughout the year. Chaplin’s World continues to attract visitors from around the world who want to explore the life and legacy of one of cinema’s most influential figures.

Located above Vevey in western Switzerland, the museum opened in 2016 and transformed the historic Ban mansion into an immersive cultural attraction. The estate served as Charlie Chaplin’s home during the final 25 years of his life after he settled in Switzerland.

Chaplin moved to Switzerland in 1953 and spent much of his later life there with his family. Today, the museum offers visitors a unique insight into his personal life, cinematic achievements, and lasting impact on the world of entertainment.

Although the record attempt did not succeed, the gathering created a memorable celebration of Charlie Chaplin’s legacy and highlighted the continued popularity of one of cinema’s greatest icons. Organisers say the anniversary events will continue to attract film enthusiasts and tourists throughout the year.

Roche Invests $700M in Cancer Drug Deal.

Swiss pharmaceutical leader Roche has entered a major partnership with California-based Nurix Therapeutics, committing $700 million to support the development of an experimental cancer treatment known as bexobrutideg. The agreement strengthens Roche’s position in the rapidly growing oncology market and highlights its continued focus on innovative cancer therapies.

Bexobrutideg is currently being developed as a treatment for chronic lymphocytic leukemia (CLL), one of the most common forms of blood cancer. The drug is expected to enter its final phase of clinical development later this year, bringing it one step closer to potential regulatory approval.

Researchers are also exploring the therapy’s potential use in treating B-cell lymphomas, as well as applications in neurology and immunology. This broader scope could significantly increase the medicine’s future commercial and medical value.

The collaboration agreement could eventually be worth as much as $2.3 billion if specific development and commercial milestones are achieved. Under the terms of the deal, Roche and Nurix will share profits and losses equally within the United States market.

Outside the United States, Nurix will receive royalty payments ranging from 10% to 20% of Roche’s revenue generated from the treatment. Roche will also assume responsibility for 60% of future development costs associated with the drug.

Industry analysts view the partnership as a strategic investment in a rapidly expanding healthcare sector. Roche estimates that the combined market for chronic lymphocytic leukemia and non-Hodgkin lymphoma treatments could reach approximately $41 billion by 2031. Within that market, therapies targeting Bruton’s tyrosine kinase are expected to account for nearly $19 billion.

The agreement demonstrates Roche’s commitment to advancing next-generation cancer treatments and expanding its oncology portfolio. If successful, bexobrutideg could provide new treatment options for patients while strengthening Roche’s leadership position in the global pharmaceutical industry.

As demand for innovative cancer therapies continues to grow worldwide, partnerships between major pharmaceutical companies and biotechnology firms are becoming increasingly important in accelerating medical breakthroughs and improving patient outcomes.

ABB CEO Warns of EU Job Crisis.

The chief executive of Swiss engineering giant ABB has issued a stark warning about Europe’s economic future, saying excessive regulation and rising energy costs could threaten competitiveness and lead to significant job losses across the European Union.

In an interview with the Financial Times, ABB CEO Morten Wierod called on EU policymakers to accelerate reforms and reduce bureaucratic barriers that he believes are slowing economic growth. He warned that failure to act quickly could result in a much deeper economic crisis and widespread unemployment.

Wierod expressed frustration over the slow implementation of recommendations proposed by former European Central Bank President Mario Draghi. According to the ABB chief, many of the suggested reforms aimed at strengthening Europe’s competitiveness have remained largely unimplemented despite being discussed for nearly two years.

The ABB leader argued that Europe must go beyond simply simplifying regulations. He believes certain rules should be removed entirely to strengthen the EU’s internal market and encourage investment, innovation, and business expansion. According to Wierod, these measures would help stimulate economic growth and improve the region’s ability to compete globally.

He also raised concerns about new European initiatives designed to reduce dependence on foreign technologies. While supporting the goal of stronger European industries, Wierod warned that strict “Made in Europe” requirements could increase costs for businesses and consumers while creating unintended economic consequences.

Another major challenge highlighted by the ABB CEO is energy pricing. Europe continues to face higher energy costs than the United States, placing manufacturers at a competitive disadvantage. Wierod noted that recent geopolitical tensions and higher gas prices are expected to keep energy costs elevated through 2026 and 2027.

Despite these concerns, Wierod emphasized that Europe still possesses significant strengths, including a highly skilled workforce, world-class education systems, and strong crisis-management capabilities. He pointed to Europe’s rapid reduction in dependence on Russian gas as evidence of the region’s ability to adapt during difficult circumstances.

The ABB chief joins a growing number of European business leaders urging policymakers to act faster. Many industry executives believe reducing red tape, encouraging innovation, and lowering business costs are essential steps to ensure Europe remains competitive in the global economy and protects future employment opportunities.

ETH Zurich Safely Removes Hazardous Chemical.

A major safety operation at ETH Zurich concluded successfully after specialists removed and transported a highly hazardous chemical substance from a former research facility. The operation was completed without any incidents, allowing evacuated residents to return to their homes later the same day.

Authorities temporarily evacuated nearly 270 residents living near the affected area as a precautionary measure. The evacuation was part of a carefully coordinated plan designed to ensure public safety while experts handled the dangerous material.

The substance involved was a gas cylinder containing chlorine trifluoride, a chemical widely recognized as one of the most hazardous compounds used in scientific research. Specialists transferred the cylinder into a specially designed recovery container before transporting it away for secure handling and disposal.

The operation began on Sunday morning and involved close coordination between ETH Zurich, emergency services, and Zurich cantonal police. Safety measures remained in place for several hours while teams completed the transfer process inside a secure laboratory environment.

Following the successful completion of the operation, authorities lifted evacuation orders and temporary traffic restrictions. Residents were allowed to return to their homes after officials confirmed that the area was safe.

Police reported that the entire operation proceeded according to plan and that all activities were carried out under strict safety protocols. No injuries, leaks, or unexpected incidents occurred during the removal process.

According to ETH Zurich, chlorine trifluoride was previously used in geological research to analyze rock samples. The chemical is highly toxic and can ignite rapidly when exposed to certain materials, making specialized handling procedures essential.

The successful operation highlights Switzerland’s strong emergency preparedness and commitment to public safety when dealing with hazardous scientific materials. Officials praised the cooperation between emergency responders, researchers, and local residents throughout the process.

Animal Rights Groups Target Migros Ads.

A coalition of Swiss animal protection organisations is preparing to file a formal complaint against supermarket giant Migros, accusing the retailer of using misleading animal welfare advertising. The complaint is expected to be submitted to Switzerland’s Fair Trading Commission in the coming days.

The action is being led by Werbemist, an alliance that includes Animal Rights Switzerland, Sentience, the Fondation pour l’animal en droit (TIR), and Tier im Fokus (TIF). The organisations argue that Migros’ advertising slogan, “Always topical: animal welfare,” creates a misleading impression about conditions within livestock farming.

According to the alliance, significant animal welfare concerns continue to exist in modern farming practices. The groups highlight issues such as painful breastbone fractures in laying hens and the use of carbon dioxide stunning methods in pigs before slaughter. They claim that these practices raise serious ethical questions and conflict with the image presented in Migros marketing campaigns.

The complaint also argues that terms such as “animal welfare” and “animal-friendly” are not legally protected in Switzerland. As a result, companies can use these phrases in advertising even when animal rights groups believe the standards do not fully reflect consumer expectations. Activists describe this practice as “welfare washing,” comparing it to other forms of marketing that present a more positive image than reality.

Migros has strongly rejected the allegations. The company states that animal welfare remains a core commitment and that standards are regularly reviewed and improved. A company spokesperson emphasized that continuous monitoring and development are part of Migros’ long-term approach to responsible food production.

The retailer also noted that improving animal welfare across the agricultural sector requires cooperation between farmers, researchers, industry partners, and government authorities. Migros believes meaningful progress can only be achieved through collaboration rather than individual action.

The dispute has sparked renewed debate in Switzerland over transparency in food production, ethical farming practices, and how animal welfare claims should be communicated to consumers. The outcome of the complaint could have broader implications for advertising standards and consumer trust within the Swiss retail sector.

Swiss Doctors Still Face Burnout Concerns.

Doctors working in Swiss hospitals are experiencing a slight reduction in weekly working hours, according to a new survey. While this marks a positive development for the healthcare sector, concerns about exhaustion and patient safety remain widespread.

The survey, conducted among 2,400 doctors by the Demoscope research institute on behalf of the Association of Swiss Assistant and Senior Physicians (VSAO), found that the average weekly workload has fallen to 54.6 hours. In 2022, doctors reported working an average of 56.3 hours per week.

The findings also show an improvement in compliance with labour regulations. The percentage of doctors reporting violations of working time laws decreased from 68% to 58%, indicating gradual progress in hospital working conditions.

Despite these improvements, fatigue continues to affect a large portion of the medical workforce. More than half of the doctors surveyed said they regularly reach a point where they feel unable to continue due to physical or mental exhaustion. The level of stress remains almost unchanged compared with previous years.

Patient safety is another major concern highlighted in the report. Nearly 60% of respondents stated that they had witnessed situations in the past two years where patients were placed at risk because of fatigue caused by excessive workloads. Medical professionals warn that long working hours and ongoing pressure can affect concentration, decision-making, and overall quality of care.

Healthcare experts believe that further reforms are needed to improve staffing levels, reduce pressure on medical teams, and protect both doctors and patients. While the reduction in working hours is a positive sign, the latest findings suggest that burnout and workplace stress continue to be serious challenges within Switzerland’s healthcare system.

The survey serves as an important reminder that maintaining a healthy and sustainable workforce is essential for delivering safe and effective healthcare across Switzerland. As hospitals face increasing demand for services, ensuring the wellbeing of medical professionals will remain a key priority.

Swiss Support for New Nuclear Plants Surges.

Public opinion in Switzerland is shifting significantly in favor of nuclear energy, with a growing number of citizens viewing it as a reliable solution to future electricity challenges. A recent survey commissioned by the Swiss Association of Electricity Companies (AES) reveals that nearly 60% of respondents support the construction of new nuclear power plants across the country.

The findings highlight increasing concerns about Switzerland’s long-term energy security. As demand for electricity continues to rise, many residents are questioning whether renewable energy sources alone will be sufficient to meet future needs. This has led to renewed interest in nuclear power as part of a balanced national energy strategy.

According to the survey, 79% of participants support keeping existing nuclear power plants in operation as long as they continue to meet safety standards. In addition, 59% favor building next-generation nuclear facilities to strengthen Switzerland’s energy infrastructure and reduce the risk of power shortages.

Energy experts believe public attitudes have changed due to growing awareness of supply risks experienced in recent years. International geopolitical tensions and concerns about global energy markets have also increased public focus on reliable domestic electricity production.

Despite the rising popularity of nuclear energy, renewable energy remains the preferred long-term solution for many Swiss citizens. Solar, wind, and hydropower continue to receive strong public support, with many respondents favoring an energy mix that combines renewables with stable backup generation.

The Swiss Parliament is expected to discuss the future direction of national energy policy, making this an important moment for Switzerland’s long-term energy planning. The debate could influence how the country balances energy security, environmental goals, and economic stability in the years ahead.

As Switzerland evaluates its energy future, nuclear power is once again becoming a central topic of discussion. The latest survey suggests that public opinion is evolving, with more citizens willing to consider nuclear energy as part of the solution to ensure a stable and secure electricity supply.

Parental Stress Becomes Major Mental Health Issue in Switzerland.

A new study conducted by AXA Switzerland has found that parental responsibility is becoming one of the leading causes of mental health challenges among adults in the country, surpassing even financial and workplace stress in its overall impact.

According to the findings, around one in four adults in Switzerland is currently affected by some form of mental health issue. The report highlights a growing concern about emotional well-being across different age groups.

Young adults between the ages of 18 and 24 are identified as the most affected group, with approximately 39% reporting mental health challenges. Experts suggest that uncertainty about education, careers, and personal life may be contributing factors.

The study also revealed a significant rise in mental health-related disability insurance claims, which have increased by nearly 78% over the past four years. This indicates a growing long-term impact on Switzerland’s workforce and social systems.

Researchers and experts point out that parenting responsibilities are placing increasing pressure on adults, especially those trying to balance work, childcare, and financial stability in a high-cost living environment.

For expatriate families living in Switzerland, the challenge is often greater due to the lack of extended family support systems. Many parents face additional emotional and logistical pressure while raising children in isolation from relatives.

Mental health professionals emphasize that this trend reflects broader societal changes, including increased work demands, rising living costs, and evolving family structures.

The study calls for stronger mental health support systems, including better access to counseling services, workplace flexibility, and family support programs to help reduce parental stress.

As mental health discussions continue to grow in Switzerland, experts stress that early intervention and community-based support will be essential in addressing the rising emotional burden on families.

Swiss Scientists Discover New Target for Treating Blindness.

Researchers led by the University of Fribourg in Switzerland have identified a promising new biological target that could lead to improved treatments for age-related macular degeneration (AMD), one of the leading causes of blindness worldwide.

The study focuses on restoring the eye’s natural cellular recycling system, which plays a critical role in maintaining retinal health. Scientists believe that failure in this system is a key driver of vision loss as people age.

AMD primarily damages photoreceptors and retinal pigment epithelial cells, which are essential for clear central vision. When these cells deteriorate, patients gradually lose the ability to see fine details, significantly affecting daily life.

The Swiss research team, led by experts in cellular biology, investigated a process known as chaperone-mediated autophagy (CMA). This system normally helps cells remove damaged proteins and maintain internal balance, but it becomes less effective with age.

According to the findings, CMA activity is crucial for retinal health, and its breakdown may directly contribute to the development of AMD. By identifying this mechanism, researchers have uncovered a potential “control point” for future therapies.

The study also explored an experimental molecule known as CA77.1, which was designed to reactivate the cell’s waste-clearing system. In laboratory models, activation of this pathway reduced inflammation and slowed cellular degeneration linked to vision loss.

Tests on cells derived from AMD patients showed improved cellular stability when the recycling mechanism was strengthened. Scientists say this suggests a new direction in treatment strategies that focus on restoring natural cell function rather than only managing symptoms.

Age-related macular degeneration affects millions globally, with risk increasing significantly after the age of 50. In older populations, the disease becomes a major cause of irreversible central vision loss, creating an urgent need for innovative therapies.

Researchers believe that targeting cellular aging mechanisms could open the door to future treatments that preserve or even restore vision. While the findings are still in early stages, they represent a significant step forward in ophthalmology research.

Switzerland continues to strengthen its position as a leading hub for medical and life sciences innovation, with this study offering new hope for addressing age-related blindness in the future.

AI-Designed Vaccine Successfully Tested in Human Trial.

Scientists at the University of Cambridge have successfully completed early human trials of a new artificial intelligence-designed vaccine called pEVAC-PS, marking a major breakthrough in medical technology and infectious disease prevention.

The vaccine was developed using advanced AI systems that analyzed global genomic data to identify shared characteristics across multiple viruses. This approach allowed researchers to design a broad-spectrum antigen capable of targeting a wide range of coronavirus-related strains.

Unlike traditional vaccines, pEVAC-PS was administered using a microfluid jet-like delivery device that injects the vaccine into the skin without a conventional needle. Researchers say this method could improve precision and patient comfort in future immunizations.

The clinical trial involved 39 healthy volunteers aged between 18 and 50. Participants were recruited from medical research centers in Southampton and Cambridge, where they received different dosage levels ranging from 0.2 mg to 1.2 mg.

The results showed that the vaccine was well tolerated, with no significant adverse side effects reported during the initial trial phase. Scientists confirmed that the study demonstrated both safety and early immune response potential.

The AI system behind the vaccine was trained to identify a common antigen structure shared among Sarbeco coronavirus family members, including SARS-CoV-2, SARS, and other related bat-origin coronaviruses. This could allow the vaccine to provide broader protection against future emerging variants.

Researchers believe this approach could revolutionize vaccine development by enabling faster design of treatments for viruses such as influenza, Ebola, and other high-risk pathogens.

Experts involved in the study say AI-driven vaccine design may significantly shorten development time and improve global preparedness for future pandemics.